Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Interpace Biosciences, Blue Cross Blue Shield enter thyroid testing contract » 17:48
02/25/21
02/25
17:48
02/25/21
17:48
IDXG

Interpace Biosciences

$3.96 /

+ (+0.00%)

Interpace Biosciences…

Interpace Biosciences announced that Blue Cross Blue Shield of Illinois has entered into an agreement to provide both coverage and in-network status for Interpace's molecular combination thyroid tests, ThyGeNEXT and ThyraMIR. The agreement is effective immediately. Tom Burnell, president and CEO of Interpace Biosciences, stated, "We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis." Mr. Burnell continued, "In the past year, we've entered into contracts with 19 health plans nationwide for coverage and in-network status for ThyGeNEXT(R) and ThyraMIR(R), reflecting continued payer adoption for our thyroid franchise."

ShowHide Related Items >><<
IDXG Interpace Biosciences
$3.96 /

+ (+0.00%)

IDXG Interpace Biosciences
$3.96 /

+ (+0.00%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$3.96 /

+ (+0.00%)

Hot Stocks
Interpace Biosciences gains acceptance for trading on OTCQX » 17:55
02/24/21
02/24
17:55
02/24/21
17:55
IDXG

Interpace Biosciences

$3.96 /

+0.03 (+0.76%)

Interpace Biosciences…

Interpace Biosciences announced that on February 24, 2021, the company satisfied the requirements for trading of the company's common stock on the OTCQX Best Market and will begin trading on OTCQX at the open of the market on February 25, 2021 under the symbol IDXG. The company previously traded on Nasdaq. "The cost-effectiveness and flexibility of the OTCQX provides our Company the opportunity to continue to excel in the public markets. We are excited about this new opportunity for our Company," stated Tom Burnell, Interpace Bioscience's President and Chief Executive Officer.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$3.96 /

+0.03 (+0.76%)

IDXG Interpace Biosciences
$3.96 /

+0.03 (+0.76%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$3.96 /

+0.03 (+0.76%)

Hot Stocks
Interpace Biosciences announces impending delisting from Nasdaq » 08:15
02/17/21
02/17
08:15
02/17/21
08:15
IDXG

Interpace Biosciences

$5.83 /

+0.16 (+2.82%)

Interpace Biosciences…

Interpace Biosciences announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff of The Nasdaq Stock Market that the Staff has determined to delist the Company's securities from Nasdaq. This determination was due to the Company's extended period of non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing set forth in listing Rule 5550(b) and the Company's failure to timely execute on its plan to comply. Unless the Company requests an appeal of this determination, trading of the Company's common stock will be suspended at the opening of business on February 25, 2021. The Company has applied to have its common stock qualified to trade on the OTCQX Best Market. The Staff reached its decision to delist the Company's common stock based upon the Company's continued non-compliance with Nasdaq Listing Rules. The Company is determining whether to appeal the determination. In the absence of such appeal trading of the Company's common stock on NASDAQ will be suspended at the opening of business on February 25, 2021, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$5.83 /

+0.16 (+2.82%)

IDXG Interpace Biosciences
$5.83 /

+0.16 (+2.82%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$5.83 /

+0.16 (+2.82%)

Hot Stocks
Interpace Biosciences CEO issues letter to shareholders on path forward » 05:48
02/17/21
02/17
05:48
02/17/21
05:48
IDXG

Interpace Biosciences

$5.83 /

+0.16 (+2.82%)

Interpace Biosciences…

Interpace Biosciences issued the following communication to shareholders: "... The Company has now put in place a restructuring and reprioritization plan, following a comprehensive evaluation of the Company's product portfolio, business model, capital allocation strategy, customer base and future opportunities. It is rooted in seeking to achieve high growth while leveraging operational efficiencies and maintaining financial discipline to achieve our vision - to be an irreplaceable segment in the continuum of quality patient care, and our mission - to assist healthcare providers in the diagnosis, triage, and treatment of patients through advanced diagnostics and novel therapeutics. To align with the Company's new strategic vision Interpace will immediately embark on several initiatives to further strengthen its profile and enhance shareholder value. These initiatives include further cost reduction events and corporate reprioritization efforts, while investing in core capabilities to ensure the Company maintains operational efficiencies and a growth profile. This is intended to reduce the cash burn. Interpace will seek to leverage opportunities to outsource functions that are not core competencies of the Company while accessing opportunities to align corporate resources with the Company's laboratories and field support teams. In total, the Company will seek to achieve annualized savings of approximately $7.2 million from its cost structure. We anticipate this will help the Company realize $4.5-$4.9 million in cost savings by the end of 2021, net of investments. Cost-savings initiatives will include reducing infrastructure costs, streamlining management, consolidating duplicative functions across both business units, and adapting to a remote work environment for non-laboratory personnel, which reduces the need for traditional office structures. Additionally, as part of its growth plans, the Company will prioritize the exploration of partnering opportunities to acquire new technologies that fit the Interpace vision with a commitment to excellence and delivering higher value at a lower cost. Further the Company will seek to grow its revenue by improving its reimbursement, entering new managed care contracts, and capitalizing on the recent opportunities related to the pricing of diagnostic testing. The Company's operational initiatives to invest in core capabilities include (1) Progressing towards new automation technology to support testing capabilities across our clinical services business in order to ensure first-in-class testing capabilities; (2) Renovating and modernizing the Pittsburgh clinical services laboratory to solidify the Company's ability to compete with top performing labs globally; (3) Improvements in overall efficiency as new technologies are transferred from development in the New Haven laboratory to commercialization in the Pittsburgh laboratory; and (4) In pharma services, exploring new clinical development capabilities with the Company's new state-of-the-art lab in Morrisville, North Carolina to maximize our ability to meet customers' needs. In addition to our cost reduction, corporate reprioritization, and growth plans, we face significant challenges with respect to our Nasdaq listing. Nasdaq requires a minimum of $2.5 million of stockholders' equity to remain listed on the exchange. The $47M preferred stock investments by our private equity investors did not qualify to be accounted for as stockholders' equity. Due primarily to this, the adverse impact of COVID-19 and the impairment charges recently announced, our current stockholders' equity deficit to remain compliant through 2021 is expected to be nearly $43 million. In anticipation of being delisted from Nasdaq, the Company has applied to be listed on the OTCQX, the highest tier over-the-counter market. The Company was notified by Nasdaq of non-compliance with the minimum stockholders' equity requirement in October 2020 and anticipated being able to cure the non-compliance in February 2021. Due to the delayed Q3 Form 10-Q filing, the $18M impairment announced in December 2020, and the re-statement of financials dating back to 2016, it was recently determined that the Company has been out of compliance with the minimum stockholders' equity requirement since the end of 2019. The Company sought to seek an extension which was denied. The Company considered various alternatives to remediate the stockholders' equity shortfall and determined that none of them were in the best interests of the Company and its stockholders primarily due to their dilutive impact to our common stockholders. On February 16, 2021, the Company received the notice of delisting from Nasdaq. The Company will remain listed on Nasdaq pending its right to appeal. We understand and share the disappointment our shareholders may have when receiving this news; however, if the process results in the Company moving to the OTCQX, there will be no minimum stockholders' equity requirement, enabling Interpace to direct 100% of its energy and focus on growth. While we recognize this is a necessary step, it will allow the Company to shape and build upon the foundation in place with a driven emphasis on visibility, lower cash spend and the prioritization of the usage of capital in a strategic manner..."

ShowHide Related Items >><<
IDXG Interpace Biosciences
$5.83 /

+0.16 (+2.82%)

IDXG Interpace Biosciences
$5.83 /

+0.16 (+2.82%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$5.83 /

+0.16 (+2.82%)

Hot Stocks
Interpace Biosciences names Tom Freeburg next CFO » 16:42
02/04/21
02/04
16:42
02/04/21
16:42
IDXG

Interpace Biosciences

$5.06 /

+0.02 (+0.40%)

Interpace Biosciences…

Interpace Biosciences announced that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace's Chief Financial Officer. Freeburg succeeds Fred Knechtel effective February 1, 2021. Freeburg has been with Interpace since 2017 and brings over 20 years of financial and executive experience to his new role. As Chief Accounting Officer, he has led the company's Financial Reporting, Treasury, Financial Planning and Analysis, Risk Management & Insurance and Corporate Development functions. Prior to Interpace, Tom served in senior finance roles at several other companies, where his responsibilities included Financial Reporting, Capital Markets, Treasury and FP&A. Thomas Burnell Ph.D., Chief Executive Officer of Interpace, commented "I would like to thank Fred for his contributions to Interpace over the last year and wish him continued success. I would also like to congratulate Tom on his appointment as CFO. He is a highly talented and experienced executive who I believe will be critical to Interpace's plans for growth. I look forward to working with Tom to define a new direction, purpose and vision for the Company that will drive profitability and enhance value for patients, physicians and shareholders alike."

ShowHide Related Items >><<
IDXG Interpace Biosciences
$5.06 /

+0.02 (+0.40%)

IDXG Interpace Biosciences
$5.06 /

+0.02 (+0.40%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$5.06 /

+0.02 (+0.40%)

Over a month ago
Hot Stocks
Interpace announces license agreement with Rutgers, Mass General Hospital » 09:30
02/01/21
02/01
09:30
02/01/21
09:30
IDXG

Interpace Biosciences

$4.11 /

-0.13 (-3.07%)

Interpace Biosciences…

Interpace Biosciences announced that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cysts, the Das-1 antibody was able to accurately identify pancreatic cysts likely to become cancerous with high sensitivity and high specificity in comparison to current clinical guidelines. Das-1 is gaining recognition among experts in the GI community as evidenced by its inclusion as a component in the Pancreatic Cyst Biomarker Alliance sponsored in part by the National Cancer Institute. The license gives Interpace exclusive commercial rights to this patented technology. The Company's flagship product, PancraGEN, was designed to provide risk assessment for pancreatic cysts using both molecular and clinical features and has been performed on more than 40,000 pancreatic cysts. This new biomarker will provide additional information regarding cancer risk to further facilitate personalized patient management. Koushik Das, MD, an assistant professor of medicine in the Division of Gastroenterology

ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.11 /

-0.13 (-3.07%)

IDXG Interpace Biosciences
$4.11 /

-0.13 (-3.07%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$4.11 /

-0.13 (-3.07%)

Hot Stocks
Interpace announces contract with Blue Cross Blue Shiled of Florida » 09:18
01/28/21
01/28
09:18
01/28/21
09:18
IDXG

Interpace Biosciences

$4.14 /

-0.21 (-4.83%)

Interpace Biosciences…

Interpace Biosciences announced that the Company's Diagnostics group has entered in to a contract with Blue Cross Blue Shield of Florida, the largest health plan in Florida. As part of the Agreement, Interpace's ThyGeNEXT and ThyraMIR tests for indeterminate thyroid nodules will be adjudicated as in-network lab services for its 5M members effective January 1. The plan agreed to cover the tests under its medical policy in 2018.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.14 /

-0.21 (-4.83%)

IDXG Interpace Biosciences
$4.14 /

-0.21 (-4.83%)

01/25/21 H.C. Wainwright
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright
10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
IDXG Interpace Biosciences
$4.14 /

-0.21 (-4.83%)

Recommendations
Interpace Biosciences price target lowered to $6 from $10 at H.C. Wainwright » 07:53
01/25/21
01/25
07:53
01/25/21
07:53
IDXG

Interpace Biosciences

$4.07 /

-0.11 (-2.63%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Interpace Biosciences to $6 from $10 and reiterates a Buy rating on the shares following the company's Q3 results. Interpace's new management team indicated that molecular test volumes recovered from the pandemic and improved in Q3, but that test volume trended downwards in December and January due to COVID-19 resurgence. As such, the analyst sees limited near-term growth for the company.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.07 /

-0.11 (-2.63%)

IDXG Interpace Biosciences
$4.07 /

-0.11 (-2.63%)

10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
04/23/20 Alliance Global Partners
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global
IDXG Interpace Biosciences
$4.07 /

-0.11 (-2.63%)

Earnings
Interpace Biosciences sees Q4 revenue $9M-$10M, consensus $8.65M  08:35
01/20/21
01/20
08:35
01/20/21
08:35
IDXG

Interpace Biosciences

$4.62 /

+0.53 (+12.96%)

 
ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.62 /

+0.53 (+12.96%)

IDXG Interpace Biosciences
$4.62 /

+0.53 (+12.96%)

10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
04/23/20 Alliance Global Partners
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global
IDXG Interpace Biosciences
$4.62 /

+0.53 (+12.96%)

Earnings
Interpace Biosciences reports Q3 EPS ($1.54), consensus ($1.20) » 08:34
01/20/21
01/20
08:34
01/20/21
08:34
IDXG

Interpace Biosciences

$4.62 /

+0.53 (+12.96%)

Reports Q3 revenue $8.2M,…

Reports Q3 revenue $8.2M, consensus $7.62M. Thomas Burnell, President and CEO of Interpace commented, "We were pleased to see improvement in clinical volumes in Q3 as the Company continued to recover from the effects of the pandemic. We exceeded the net revenue guidance previously provided, driven by higher molecular test volume, higher reimbursement rates and realization of our ThyraMIR price increase in the third quarter. In January, we began to realize reimbursement on the Medicare ThyGeNEXT price increase. We experienced improved business trends through the third quarter and into the fourth quarter; we currently expect Fourth Quarter Net Revenue to be in the range of $9 million to $10 million, subject to review and audit. However, in December and January we are seeing lower testing volume due to increased COVID cases. Additionally, we are pleased to announce that on January 7th we successfully closed on a $5 million secured bridge loan with our existing equity investors, Ampersand Capital Partners and 1315 Capital Partners, which further demonstrates their commitment as a strategic partner to the Company. Concurrently, we terminated our credit facility with Silicon Valley Bank, which had no borrowing availability. As of January 15th we had a cash balance of $6.1 million, net of restricted cash."

ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.62 /

+0.53 (+12.96%)

IDXG Interpace Biosciences
$4.62 /

+0.53 (+12.96%)

10/22/20 Alliance Global Partners
Interpace price target lowered to $7 from $9.25 at Alliance Global Partners
10/22/20 H.C. Wainwright
Interpace Biosciences price target lowered to $10 from $11 at H.C. Wainwright
06/26/20 H.C. Wainwright
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright
04/23/20 Alliance Global Partners
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global
IDXG Interpace Biosciences
$4.62 /

+0.53 (+12.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.